Skip to main content

Phthisis Diagnostics Reels In $549K in Grants

NEW YORK (GenomeWeb News) – Phthisis Diagnostics yesterday said that it has brought in $548,877 in grants from the Commonwealth of Virginia to support development and commercialization of its molecular diagnostic products.

The Charlottesville, Va.-based firm said that it received a $499,477 Commercialization Program grant and a Small Business Innovation Research Matching Fund award of $49,400 through the Commonwealth Research Commercialization Fund. Phthisis said it was one of only four companies in Virginia to receive a Commercialization Program grant.

"This funding will support development and launch of two molecular diagnostic kits that will fulfill a critical need for better diagnosis of intestinal parasites," Crystal Icenhour, president and chief science officer of Phthisis, said in a statement.

Phthisis was founded in 2005 and has developed a range of molecular diagnostic products under the Simply Molecular brand name. Its first product, the E-Sphere Stool DNA Extraction Kit, was launched this past May.

The Scan

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.